Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcium dobesilate (calcium hydroxybenzene sulphonate) is a synthetic vasoprotective agent primarily used to treat microvascular disorders, including diabetic retinopathy and chronic venous insufficiency. It acts by improving capillary resistance, reducing capillary permeability, and decreasing blood viscosity. Additionally, it enhances lymphatic drainage and exhibits anti-inflammatory and antioxidant properties by modulating the activity of various mediators such as histamine, bradykinin, and vascular endothelial growth factor (VEGF). Originally developed by Laboratoires OM (now Vifor Pharma), it is marketed under the brand name Doxium and is available in various oral formulations, including tablets and capsules.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium dobesilate (CSL Vifor).